Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions
AEG Osman, MW Deininger - Blood reviews, 2021 - Elsevier
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by a reciprocal
translocation [t (9; 22)(q34; q11. 2)] that leads to the fusion of ABL1 gene sequences (9q34) …
translocation [t (9; 22)(q34; q11. 2)] that leads to the fusion of ABL1 gene sequences (9q34) …
How I monitor residual disease in chronic myeloid leukemia
JP Radich - Blood, The Journal of the American Society of …, 2009 - ashpublications.org
Molecular monitoring in chronic myeloid leukemia (CML) is a powerful tool to document
treatment responses and predict relapse. Nonetheless, the proliferation of clinical trials and …
treatment responses and predict relapse. Nonetheless, the proliferation of clinical trials and …
Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study
A Hochhaus, C Gambacorti-Passerini, C Abboud… - Leukemia, 2020 - nature.com
Bosutinib is approved for newly diagnosed Philadelphia chromosome-positive (Ph+) chronic
phase (CP) chronic myeloid leukemia (CML) and for Ph+ CP, accelerated (AP), or blast (BP) …
phase (CP) chronic myeloid leukemia (CML) and for Ph+ CP, accelerated (AP), or blast (BP) …
A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma
JWB De Groot, BA Zonnenberg… - The Journal of …, 2007 - academic.oup.com
Context: Medullary thyroid carcinoma (MTC) metastasizes early in its clinical course. No
effective systemic therapy is available. Generally (somatic or germline), mutations in the …
effective systemic therapy is available. Generally (somatic or germline), mutations in the …
Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I–induced leukemia and suppresses leukemic stem cells
C Peng, J Brain, Y Hu, A Goodrich… - Blood, The Journal …, 2007 - ashpublications.org
Abstract Development of kinase domain mutations is a major drug-resistance mechanism for
tyrosine kinase inhibitors (TKIs) in cancer therapy. A particularly challenging example is …
tyrosine kinase inhibitors (TKIs) in cancer therapy. A particularly challenging example is …
A general strategy for the synthesis of α-trifluoromethyl-and α-perfluoroalkyl-β-lactams via palladium-catalyzed carbonylation
Y Li, CL Zhang, WH Huang, N Sun, M Hao… - Chemical …, 2021 - pubs.rsc.org
β-Lactam compounds play a key role in medicinal chemistry, specifically as the most
important class of antibiotics. Here, we report a novel one-step approach for the synthesis of …
important class of antibiotics. Here, we report a novel one-step approach for the synthesis of …
Effects of imatinib on monocyte-derived dendritic cells are mediated by inhibition of nuclear factor-κB and Akt signaling pathways
S Appel, A Rupf, MM Weck, O Schoor… - Clinical Cancer …, 2005 - AACR
Dendritic cells are the most powerful antigen-presenting cells playing a decisive role for the
initiation and maintenance of primary immune responses. However, signaling pathways …
initiation and maintenance of primary immune responses. However, signaling pathways …
KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib
D Marin, IH Gabriel, S Ahmad, L Foroni… - Leukemia, 2012 - nature.com
Natural killer (NK) cells are expanded in chronic myeloid leukemia (CML) patients on
tyrosine kinase inhibitors (TKI) and exert cytotoxicity. The inherited repertoire of killer …
tyrosine kinase inhibitors (TKI) and exert cytotoxicity. The inherited repertoire of killer …
Efficacy of imatinib mesylate in the treatment of refractory sclerodermatous chronic GVHD
L Magro, B Catteau, V Coiteux, B Bruno… - Bone marrow …, 2008 - nature.com
Abstract Treatment of sclerodermatous chronic GVHD (cGVHD) remains disappointing.
Imatinib mesylate enables selective, dual inhibition of the transforming growth factor β …
Imatinib mesylate enables selective, dual inhibition of the transforming growth factor β …
Adherence to tyrosine kinase inhibitor therapy for chronic myeloid leukemia: a Brazilian single-center cohort
MH de Almeida, KBB Pagnano, AC Vigorito… - Acta …, 2013 - karger.com
The introduction of oral tyrosine kinase inhibitors (TKIs) has dramatically improved outcomes
in chronic myeloid leukemia (CML) patients. However, treatment success is directly related …
in chronic myeloid leukemia (CML) patients. However, treatment success is directly related …